Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): An 8-year observational study at a single center

Medicine (United States)

Volumn 93, Issue 24, 2014, Pages 333-339

  Izzedine, Hassan ^a,d   Escudier, Bernard ^b   Lhomme, Catherine ^b   Pautier, Patricia ^b   Rouvier, Philippe ^a   Gueutin, Victor ^a   Baumelou, Alain ^a   Derosa, Lisa ^b   Bahleda, Rastilav ^b   Hollebecque, Antoine ^b   Sahali, Djillali ^c   Soria, Jean Charles ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d Monceau Park International Clinic   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; NEBIVOLOL; PROTEIN TYROSINE KINASE INHIBITOR; SYNAPTOPODIN; THIAZIDE DIURETIC AGENT; VASCULOTROPIN INHIBITOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN A;

ADENOCARCINOMA; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CANCER GROWTH; CAUSE OF DEATH; CLINICAL FEATURE; COHORT ANALYSIS; COLLAPSING LIKE FOCAL SEGMENTAL GLOMERULOSCLEROSIS; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; GLIOBLASTOMA; GLOMERULOPATHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BIOPSY; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; LEIOMYOSARCOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MEMBRANOUS GLOMERULONEPHRITIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSMISSION ELECTRON MICROSCOPY; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; LIPOID NEPHROSIS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NEPHROSIS, LIPOID; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; RECEPTOR PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 84926022649     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000207     Document Type: Article

References (31)

1. Albaqumi M, Barisoni L. Current views on collapsing glomerulopathy. J Am Soc Nephrol. 2008;19:1276-1281.
2. Barakat RK, Singh N, Lal R, et al. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother. 2007;41:707-710.
3. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIVassociated nephropathy. J Am Soc Nephrol. 1999;10:51-61.
4. Bhadada SV, Goyal BR, Patel MM. Angiogenic targets for potential disorders. Fundam Clin Pharmacol. 2010;25:29-47.
5. Bollee G, Patey N, Cazajous G, et al. Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant. 2009;24:682-685.
6. Cohen AH, Sun NC, Shapshak P, Imagawa DT. Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol. 1989;2:125-128.
7. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis. 2004;43:368-382.
8. Dvorak HF. Angiogenesis: update. J Thromb Haemost. 2005;3:1835- 1842.
9. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129- 1136.
10. Eremina V, Quaggin SE. Biology of anti-angiogenic therapy induced thrombotic microangiopathy. Semin Nephrol. 2010;30:582-590.
11. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716.
12. Frangie C, Lefaucheur C, Medioni J, et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol. 2007;8:177-178.
13. Garovic VD, Wagner SJ, Petrovic LM, et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant. 2007;22:1136-1143.
14. Haas M. Collapsing glomerulopathy: Many means to a similar end. Kidney Int. 2008;73:669-671.
15. Izzedine H, Brocheriou I, Deray G, Rixe O.
16. Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabineinduced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21:3038-3045.
17. Izzedine H, Mangier M, Ory V, et al. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int. 2014;85:457-470.
18. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibitioninduced proteinuria: mechanisms, significance and management. Eur J Cancer. 2010;46:439-448.
19. Kapiteijn E, Brand A, Kroep J, Gelderblom H. sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Ann Oncol. 2007;18:1745-1747.
20. Laurinavicius A, Rennke HG. Collapsing glomerulopathy-A new pattern of renal injury. Semin Diagn Pathol. 2002;19:106-115.
21. Levey SA, Bajwa RS, Picken MM, et al. Thrombotic microangiopathy associated with sunitinib, a veGF inhibitor, in a patient with factor v Leiden mutation. NDT Plus. 2008;1:154-156.
22. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
23. Muller-Deile J, Worthmann K, Saleem M, et al. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am J Physiol Renal Physiol. 2009;297:F1656-F1667.
24. Roncone D, Satoskar A, Nadasdy T, et al. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol. 2007;3:287-293.
25. Salvatore SP, Barisoni LMC, Herzenberg AM, et al. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol. 2012;7:914-925.
26. Schrijvers BF, Flyvbjerg A, de Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65:2003-2017.
27. Sugimoto H, Hamano Y, Charytan D, et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-12608.
28. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int. 2004;66:1145-1152.
29. Vigneau C, Lorcy N, Dolley-Hitze T, et al. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study. Nephrol Dial Transplant. 2014;29:325- 332.
30. Winston JA, Bruggeman LA, Ross MD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med. 2001;344:1979-1984.
31. Zhao S, Gu X, Groome LJ, Wang Y. Decreased nephrin and GLEPP-1, but increased VEGF, Flt-1, and nitrotyrosine, expressions in kidney tissue sections from women with preeclampsia. Reprod Sci. 2009;16:970-979.